Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.76) by $0.28. During the same period in the prior year, the company earned ($0.34) earnings per share. On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Atea Pharmaceuticals Stock Up 1.5 %

NASDAQ AVIR traded up $0.05 during trading on Friday, hitting $3.29. The company's stock had a trading volume of 77,369 shares, compared to its average volume of 301,281. Atea Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $4.60. The firm has a 50 day moving average price of $3.59 and a 200 day moving average price of $3.63. The firm has a market cap of $277.74 million, a P/E ratio of -1.54 and a beta of 0.17.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AVIR. Morgan Stanley upgraded Atea Pharmaceuticals from an "underweight" rating to an "equal weight" rating and increased their price objective for the stock from $2.00 to $6.88 in a research note on Tuesday, August 13th. William Blair upgraded Atea Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th.

Insider Buying and Selling at Atea Pharmaceuticals

In other news, CEO Jean-Pierre Sommadossi sold 33,941 shares of the company's stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $4.05, for a total value of $137,461.05. Following the transaction, the chief executive officer now owns 5,890,053 shares of the company's stock, valued at approximately $23,854,714.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 17.80% of the company's stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.